Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam.

SPECIAL REPORT

HIV / AIDS

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021

Bacterial InfectionsDrug Resistance

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa

Clin Infect Dis.

Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F

doi: 10.1093/cid/ciz816.

Bacterial Infections

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

doi: 10.1093/ofid/ofz505.

Drug Resistance

Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection

Clin Microbiol Infect.

Viasus D, Puerta-Alcalde P, Cardozo C, Suárez-Lledó M, Rodríguez-Núñez O, Morata L, Fehér C, Marco F, Chumbita M, Moreno-García E, Fernández-Avilés F, Gutiérrez-Garcia G, Martínez JA, Mensa J, Rovira M, Esteve J, Soriano A, Garcia-Vidal C, Hospital Clínic, Barcelona, Spain.

doi: 10.1016/j.cmi.

Bacterial Infections

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study

Clin Infect Dis.

Babich T, Naucler P, Valik JK, Giske CG, Benito N, Cardona R, Rivera A, Pulcini C, Abdel Fattah M, Haquin J, Macgowan A, Grier S, Gibbs J, Chazan B, Yanovskay A, Ben Ami R, Landes M, Nesher L, Zaidman-Shimshovitz A, McCarthy K, Paterson DL, Tacconelli E, Buhl M, Mauer S, Bano JR, Morales I, Oliver A, Ruiz de Gopegui E, Cano A, Machuca I, Gozalo-Marguello M, Martinez LM, Gonzalez-Barbera EM, Alfaro IG, Salavert M, Beovic B, Saje A, Mueller-Premru M, Pagani L, Vitrat V, Kofteridis D, Zacharioudaki M, Maraki S, Weissman Y, Paul M, Dickstein Y, Leibovici L, Yahav D

doi: 10.1093/cid/ciz668.

Respiratory Tract Infection

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Lancet Infect Dis.

GBD 2016 Lower Respiratory Infections Collaborators

doi: 10.1016/S1473-

Respiratory Tract Infection

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study

Lancet Infect Dis.

Zürcher K, Ballif M, Fenner L, Borrell S, Keller PM, Gnokoro J, Marcy O, Yotebieng M, Diero L, Carter EJ, Rockwood N, Wilkinson RJ, Cox H, Ezati N, Abimiku AG, Collantes J, Avihingsanon A, Kawkitinarong K, Reinhard M, Hömke R, Huebner R, Gagneux S, Böttger EC, Egger M, International epidemiology Databases to Evaluate AIDS (IeDEA) consortium

doi: 10.1016/S1473-3099(18)30673-X.

Bacterial Infections

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019

Open Forum Infect Dis

Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, Sahm DF

doi: 10.1093/ofid/ofab320

Respiratory Tract Infection

Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study

Lancet Respir Med.

Man WH, van Houten MA, Mérelle ME, Vlieger AM, Chu MLJN, Jansen NJG, Sanders EAM, Bogaert D

doi: 10.1016/S2213-2600(18)30449-1.

Related content

11e Conférence de la Société internationale sur le SIDA (IAS) 2021

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection

Ceftazidime, carbapenems, or piperacillin-tazobactam as single definitive therapy for Pseudomonas aeruginosa bloodstream infection - a multi-site retrospective study

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016

Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study

Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019

Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study

11^e Conférence de la Société internationale sur le SIDA (IAS) 2021